



J. B. Chemicals & Pharmaceuticals Limited

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

J.B.Chemicals declares robust profits for 2009-10.

Mumbai, May 05, 2010: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its audited financial results for the financial year ended on March 31, 2010. The highlights of these results are as under:

Stand-alone Results: Highlight for the 4th Quarter:

(Rs. in crores)

Sales	165.72	Up 6.80% over the same quarter last year
PBT	31.20	Up 152.58% over the same quarter last year
PAT	26.98	UP 117.83% over the same quarter last year
EPS (Rs.)(FV Rs. 2)	3.20	UP 117.69% over the same quarter last year

Stand-alone Results: Highlight for the year 2009-10:

(Rs. in crores)

Sales	670.06	Down 7.34% over the last year
PBT	120.94	Up 31.78% over the last year
PAT	100.99	UP 28.27% over the last year
EPS (Rs.)(FV Rs. 2)	11.98	UP 28.27% over the last year

Consolidated Results: Highlight for the year 2009-10:

(Rs. in crores)

Sales	740.97	Up 3.33% over the last year
PBT	148.07	Up 299.59% over the last year
PAT	118.75	Up 361.90% over the last year
EPS (Rs.)(FV Rs. 2)	14.08	Up 361.64% over the last year

The overall performance of the company has been satisfactory. The sales in Domestic, Russia and the Rest of the world markets have all shown growth at consolidated level. The company effected change in distribution system in Russia last year has reflected in higher consolidated profits in 2009-10. The improved

performance of the company's South African joint venture has also helped increase consolidated sales and profits.

Dividend:

The board of directors has recommended dividend of Rs. 2 (100%) per equity share of face value of Rs.2. This will absorb Rs. 19.68 crores including dividend distribution tax.

New Growth Initiatives:

In order to support future growth, the company during the year 2010-11 plans to invest total of about Rs. 40 crores in (a) further modernization and efficiency enhancement of the formulations facility at Kadaiya and Panoli, (b) new R&D activities, which will *inter alia* facilitate filing of new products registration applications in important markets, and (c) increase in field force to strengthen rural marketing initiatives in domestic market as well as increase in marketing activities in Russia & CIS countries to provide additional impetus to the marketing plans. These initiatives are expected to provide new growth opportunities.

Keeping in view future growth objectives, the board of directors has approved acquisition of 10 acres of land at Pharma specific Special Economic Zone at Panoli for setting up formulations unit. Subject to necessary approvals, the company plans for this proposed unit to be functional by Q4 of 2012-13.

All these investments will be met out of internal accruals.

The company has placed an increased focus on domestic formulations business and encouraged by the success of key brands, the company has chalked out a plan to strengthen its foot prints in rural market that holds enormous growth potential. The company would continue to follow aggressive marketing strategies particularly in key markets of Russia and CIS countries where the company's major sales come from OTC range of products.

The company has entered into newer contract manufacturing opportunities with several leading multinationals for supply of Lozenges.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.